Different results were obtained in another more homogeneous retrospective cohort of patients (only those with resected lung adenocarcinoma were included), where the expression of PD-L2 by tumor cells (1% cut-off) was associated with worse outcomes (shorter disease-free survival and OS),22 probably related to the different patient population evaluated. This evidence concerns the gene PDCD1LG2 and lung adenocarcinoma.